18889881171
Kalkine 0
countryflagUS

Sana Biotechnology Inc

Healthcare US SANA

4.125USD
-0.095(2.25%)

Last update at 2025-07-15T16:59:00Z

Day Range

4.114.27
LowHigh

52 Week Range

2.7512.00
LowHigh

Fundamentals

  • Previous Close 4.22
  • Market Cap1776.45M
  • Volume2641075
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-329.69101M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -269.47600M -355.92800M -285.30500M -138.32500M -
Minority interest - - - - -
Net income -266.38800M -344.18200M -278.63700M -130.77800M -
Selling general administrative 71.56M 50.41M 28.27M 21.78M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 15.62M 11.07M 5.92M 1.83M -
Ebit -288.18900M -367.97900M -292.07000M -141.15200M -26.49200M
Ebitda -272.56400M -356.90900M -286.14900M -139.32600M -
Depreciation and amortization 15.62M 11.07M 5.92M 1.83M -
Non operating income net other -0.67400M 0.30M - - -
Operating income -272.56400M -356.90900M -286.14900M -141.15200M -
Other operating expenses 272.56M 356.91M 286.15M 141.15M -
Interest expense -15.62500M 11.07M 0.00000M 2.83M 0.00000M
Tax provision - 0.00000M 0.00000M -7.54700M -
Interest income 3.76M 0.68M 0.75M 2.86M -
Net interest income 3.76M 0.68M 0.75M 2.86M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.08800M -11.74600M -6.66800M -7.54700M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 272.56M 356.91M 286.15M 141.15M -
Cost of revenue - - - - -
Total other income expense net 3.09M 0.98M 0.84M 2.83M -
Discontinued operations - - - - -
Net income from continuing ops -269.47600M -355.92800M -285.30500M -130.77800M -
Net income applicable to common shares -269.47600M -355.92800M -285.30500M -130.77800M -26.49400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 565.30M 822.72M 1129.41M 730.30M 415.70M
Intangible assets 59.20M 59.20M 59.20M 59.20M 59.20M
Earning assets - - - - -
Other current assets 4.49M 14.37M 7.11M 6.20M 5.28M
Total liab 277.79M 323.40M 400.90M 1151.48M 558.24M
Total stockholder equity 287.51M 499.31M 728.50M -421.18400M -142.54200M
Deferred long term liab - - - - -
Other current liab 47.18M 96.25M 56.38M 25.49M 17.98M
Common stock 0.02M 0.02M 0.02M 0.00200M 0.00100M
Capital stock 0.02M 0.02M 0.02M 0.00200M 0.00100M
Retained earnings -1338.09100M -1054.83600M -785.36000M -429.43200M -144.12700M
Other liab - 116.04M 199.89M 198.94M 74.69M
Good will 140.63M 140.63M 140.63M 140.63M 140.63M
Other assets - 9.01M 13.82M 2.33M 2.30M
Cash 137.35M 176.76M 253.03M 412.00M 80.03M
Cash and equivalents - - - - -
Total current liabilities 64.49M 111.50M 99.23M 31.45M 19.83M
Current deferred revenue - - 31.48M - -
Net debt -33.25300M -68.51200M -142.08600M -340.08600M -31.82300M
Short term debt 13.20M 12.39M 9.16M 3.71M 1.85M
Short long term debt - - - - -
Short long term debt total 104.10M 108.25M 110.94M 71.91M 48.21M
Other stockholder equity 1625.64M 1558.46M 385.80M -844.68100M 1.56M
Property plant equipment - 66.92M 65.46M 109.94M 68.81M
Total current assets 213.51M 444.44M 558.10M 384.47M 144.26M
Long term investments 0.00000M 10.05M 195.88M 33.73M -
Net tangible assets - 299.49M 528.68M -621.00600M -342.36400M
Short term investments 71.68M 247.20M 297.97M 253.46M 58.95M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.11M 2.86M 2.22M 2.25M 0.00000M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.06000M -4.32700M -1.36600M 0.03M 0.03M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.00200M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -1054.83600M -785.36000M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.37M 9.01M 13.82M 2.33M 2.30M
Deferred long term asset charges - - - - -
Non current assets total 351.78M 378.28M 571.31M 345.83M 271.44M
Capital lease obligations 104.10M 108.25M 110.94M 71.91M 48.21M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 231.44M -211.36200M -228.69100M -58.54200M -0.64000M
Change to liabilities 11.97M 5.57M 1.98M -0.42100M 0.58M
Total cashflows from investing activities 210.56M -245.79800M -252.56300M -87.86100M -1.56000M
Net borrowings - - - - -
Total cash from financing activities 4.91M 631.75M 435.69M 223.73M 91.44M
Change to operating activities 6.48M 10.07M 4.17M 10.95M -1.19400M
Net income -269.47600M -355.92800M -285.30500M -130.77800M -26.49400M
Change in cash -74.57500M 134.90M 45.14M 50.36M 62.89M
Begin period cash flow 261.85M 126.95M 81.81M 31.45M -
End period cash flow 187.27M 261.85M 126.95M 81.81M 31.45M
Total cash from operating activities -290.05000M -251.05400M -137.98200M -85.50400M -26.99000M
Issuance of capital stock 0.60M 626.40M 435.69M 223.74M -
Depreciation 15.62M 11.07M 5.92M 1.83M 0.00200M
Other cashflows from investing activities - -4.57400M -4.57400M -4.57400M -4.57400M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.60M 626.40M - - -
Other cashflows from financing activities 4.31M 5.35M 435.54M 223.72M -49.22000M
Change to netincome 25.67M 51.13M 135.25M 32.92M 0.12M
Capital expenditures 20.88M 29.86M 23.87M 26.18M 0.92M
Change receivables - - - - -
Cash flows other operating -73.83800M 37.10M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -74.57500M 134.90M - - -
Change in working capital 7.54M 9.80M 6.16M 10.53M -
Stock based compensation 38.34M 22.36M 5.83M 1.50M -
Other non cash items -82.07800M 61.64M 129.42M 38.97M -
Free cash flow -310.92600M -280.91600M -161.85400M -111.68700M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
SANA
Sana Biotechnology Inc		 -0.095 2.25% 4.12 - - - 6.86 -6.9695
NVO
Novo Nordisk A/S		 -1.45 2.10% 67.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 67.01 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.85 1.66% 464.50 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -18.155 3.18% 552.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology Inc

188 East Blaine Street, Seattle, WA, United States, 98102

Key Executives

Name Title Year Born
Dr. Steven D. Harr M.D. Pres, CEO & Director 1970
Dr. Richard C. Mulligan Ph.D. Exec. Vice Chairman & Head of SanaX 1955
Mr. Nathan Hardy M.B.A. Exec. VP & CFO 1976
Dr. Sunil Agarwal M.D. Exec. VP, Head of Devel. & Chief Medical Officer 1970
Ms. Shanna Clouse Peek Sr. VP & Head of Corp. Operations NA
Brittany Mccleery Accounting Mang. NA
Dr. Edward Rebar Ph.D. Sr. VP & CTO 1968
Mr. Bernard J. Cassidy J.D. Exec. VP & Gen. Counsel 1955
Ms. Robin Andrulevich Exec. VP & Chief People Officer 1966
Mr. Paul Brunetta M.D. Sr. VP and Head of Clinical & Translational Science NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.